These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 35126672)
1. Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract. Wang H; Palasik BN Ther Adv Urol; 2022; 14():17562872211065570. PubMed ID: 35126672 [TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis. Kawaguchi N; Katsube T; Echols R; Wajima T Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29038272 [TBL] [Abstract][Full Text] [Related]
4. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675 [TBL] [Abstract][Full Text] [Related]
5. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE). Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487 [TBL] [Abstract][Full Text] [Related]
6. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety. Lee YR; Yeo S Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. Jorda A; Zeitlinger M Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355 [No Abstract] [Full Text] [Related]
14. Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence. Wang C; Yang D; Wang Y; Ni W Front Pharmacol; 2022; 13():896971. PubMed ID: 35496290 [TBL] [Abstract][Full Text] [Related]
15. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196 [TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection. Kawaguchi N; Katsube T; Echols R; Wajima T Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257454 [TBL] [Abstract][Full Text] [Related]